This Article Abstract Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chevalley, T. Articles by Rizzoli, R. Search for Related Content PubMed PubMed Citation Articles by Chevalley, T. Articles by Rizzoli, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL Medline Plus Health Information Dietary Supplements Related Collections Adrenal and Hypertension

Skeletal Site Selectivity in the Effects of Calcium Supplementation on Areal Bone Mineral Density Gain: A Randomized, Double-Blind, Placebo-Controlled Trial in Prepubertal Boys

Service of Bone Diseases (World Health Organization Collaborating Centre for Osteoporosis Prevention), Department of Rehabilitation and Geriatrics (T.C., J.-P.B., S.F., R.R.) and Service of Nuclear Medicine, Department of Radiology (D.H.), University Hospitals of Geneva, CH-1211 Geneva 14, Switzerland

Address all correspondence and requests for reprints to: Thierry Chevalley, M.D., Service of Bone Diseases, Department of Rehabilitation and Geriatrics, University Hospitals of Geneva, CH-1211 Geneva 14, Switzerland. E-mail: thierry.chevalley{at}hcuge.ch.

	Abstract

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Background: Calcium supplementation during childhood and adolescence is considered an early means of preventing osteoporosis in adults. Prepuberty is an opportune time for detecting the benefits of calcium in girls.

Objective: The objective was to assess whether calcium supplementation increases bone mass gain in prepubertal boys in a skeletal site-specific manner.

Methods: In a 12-month double-blind, placebo-controlled trial with 1-yr follow-up, 235 healthy prepubertal boys aged 7.4 ± 0.4 yr (mean ± SD) were randomized to receive two food products providing 850 mg/d calcium (calcium supplement group, n = 116) or an isocaloric placebo (n = 119). Areal bone mineral density (aBMD) was determined by dual-energy x-ray absorptiometry at radius (two sites), hip (two sites), femoral diaphysis (FDia), and L2–L4 vertebrae.

Results: At 12 months, aBMD gain was greater at the FDia and at the mean of the five appendicular skeletal sites in the calcium supplement group in both intention-to-treat analysis [76 ± 32 vs. 64 ± 33 mg/cm²·yr; difference, 12.0 (95% confidence interval, CI, 3.6–20.3), P = 0.006; and 33 ± 16 vs. 28 ± 16 mg/cm²·yr; difference, 5.1 (95% CI, 0.9–9.2); P = 0.018, respectively] and active treatment analysis [81 ± 32 vs. 64 ± 31 mg/cm²·yr; difference, 17.2 (95% CI, 7.9–26.5); n = 174, P < 0.001; and 35 ± 16 vs. 28 ± 14 mg/cm²·yr; difference, 7.5 (95% CI, 2.9–12.2); P = 0.002]. There was no beneficial effect of calcium on lumbar spine. The calcium effect was still detectable by ANOVA repeated measures analysis at the FDia (P = 0.004) and at the mean of the five appendicular skeletal sites (P = 0.002) 1 yr after the end of intervention (active treatment analysis). There was no change in bone size.

Conclusion: In prepubertal boys, calcium-enriched foods increased aBMD at several appendicular skeleton sites, but not at the lumbar spine, and this without any bone size change. This effect was maintained 1 yr after treatment discontinuation.

	Introduction

Top Abstract Introduction Subjects and Methods Results Discussion References

 
OSTEOPOROSIS IS A disease that affects not only many women but also an increasing number of men with the aging of the population. At the age of 50, lifetime risk of fracture in men is greater than 20% (1). In addition to age-related bone loss, the amount of bone acquired during childhood and adolescence that determines the so-called peak bone mass is a major determinant of osteoporotic fracture risk later in life. Increasing calcium intake during childhood and adolescence may result in higher peak bone mass by promoting a greater bone mass gain, as shown in prospective randomized, double-blind, placebo-controlled intervention trials (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12). All of these studies assessed girls only or both genders but did not specifically include prepubertal boys. In a previous 12-month intervention study in prepubertal girls, we observed that calcium-induced bone mass gain could quantitatively differ according to the skeletal sites examined, the most significant areal bone mineral density (aBMD) response being observed at the level of both radial and femoral diaphysis (FDia) (11). Furthermore, it was associated with an increase in bone size (11). The beneficial effect of calcium on bone mass gain recorded at the end of the intervention period in prepubertal girls appeared to be maintained by 1, 3.5, and 7.5 yr after treatment discontinuation (11, 13, 14). Based on previous published results, it has been assumed that calcium supplementation in childhood would be beneficial in both genders. However, due to the lack of precise information in males, we decided to specifically revisit the question. Therefore, the aims of the present randomized, double-blind, placebo-controlled study, carried out in a homogenous cohort of prepubertal boys, were to assess whether calcium supplementation increases bone mass gain and whether this effect is: 1) skeletal site selective; 2) associated with an increased bone size; and 3) maintained 1 yr after the end of intervention.

	Subjects and Methods

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Subjects and study design

Healthy prepubertal Caucasian boys were recruited through the Public Health Youth Service of the Geneva region from September 1999 to September 2000. The protocol was approved by the Ethics Committee of the Department of Pediatrics of the University Hospitals of Geneva. Informed consent was obtained from the parents and their children. Families of 4150 boys were invited by mail to fill out a 7-d dietary diary. From this first step, 990 analyzable diaries were received (Fig. 1). Boys with a spontaneous calcium intake below the 75th percentile were recontacted and invited to participate in the intervention trial because we previously observed a greater effect of calcium supplementation on aBMD gain in prepubertal girls with a spontaneous calcium intake below the median (11). A total of 235 subjects were enrolled after applying the following exclusion criteria: weight to height ratio below the third or above the 97th percentile according to Geneva reference values, presence of physical signs of puberty, chronic disease, gastrointestinal disease with malabsorption, congenital or acquired bone disease, and regular use of medication. They were randomized into two groups receiving either calcium-enriched foods [calcium supplement (Ca-suppl.)] or placebo foods for 12 months. Enrolled subjects were further stratified according to the median of their spontaneous calcium intake, and those with relatively low or high calcium intakes were distributed in equal numbers in both groups. An additional examination took place 1 yr after the end of intervention.

View larger version (28K): [in this window] [in a new window]   FIG. 1. Flow of participants. Numbers of subjects are given at each step of the study. Among the 4150 boys contacted, 990 completed a 7-d dietary diary. Boys with a spontaneous calcium intake based on a 7-d dietary diary below the 75th percentile were selected. Subjects were then stratified into two strata according to the median of the spontaneous calcium intake of the cohort before assignment to the treatment arms.

Calcium-phosphate salt extracted from milk was used to enrich several food products: chocolate or caramel cakes, biscuits, fruit juices, powdered drinking chocolate, and chocolate bars. On average, the consumption of two calcium-enriched servings per day provided a Ca-suppl. of about 850 mg. Two very similar food products with respect to energy, proteins, and lipids, but without added milk calcium-phosphate salt, were consumed daily by the control (placebo) group. The mean nutrient contents of the milk calcium-phosphate salt foods and placebo were: calcium, 436 and 46 mg; phosphate, 236 and 54 mg; lipids, 6.6 and 6.6 g; carbohydrates, 22.9 and 22.4 g; proteins, 2.3 and 2.2 g; and energy, 160 and 158 kcal, respectively. Over the entire intervention period, each subject received one set of food products every month. Parents were instructed to encourage their sons to consume two food products every day, instead of similar servings usually taken for breakfast or snacks. Compliance was recorded by the parents and verified through regular phone calls and interviews by a trained dietician.

Calcium intake assessment

The spontaneous calcium intakes were assessed by frequency questionnaires at baseline and 6, 12, and 24 months. The mean of the three questionnaires at 0, 6, and 12 months was taken into account for analyzing the relationship between nutritional intakes and anthropometric or bone variables.

Physical activity assessment

Usual physical activity and weight-bearing physical activity were recorded and measured in hours per week (15) or in kilocalories per day after the coding of physical activities in energy costs (16). It included physical education classes, organized sports, recreational activity, and usual walking and cycling.

Measurement of anthropometric and bone variables

At baseline and 12 and 24 months, we measured participants’ weight and standing height using a stapediometer, and body mass index (BMI) was calculated. aBMD was determined by dual-energy x-ray absorptiometry using a Hologic QDR 4500 instrument (Hologic, Waltham, MA). Six skeletal sites were examined: radius [distal metaphysis (RMet) and diaphysis], hip (femoral neck and trochanter), FDia, and L2–L4 vertebrae [lumbar spine (LS)] in anteroposterior view as previously reported (11). The coefficient of variation of repeated measurements at these sites as determined in young healthy adults varied from 1.0–1.6% for BMD and from 0.3–3.0% for bone mineral content (BMC) and projected bone scanned area.

Expression of the results and statistical analysis

Differences in the anthropometric and osteodensitometric gains between the Ca-suppl. and the placebo groups were computed by intention-to-treat analysis (ITT) that included all subjects who entered the study and had measurements repeated at 1 yr. Differences were further calculated by active treatment analysis (AT) that included the subjects who consumed the tested foods until the end of the intervention year. Taking into account the precision of the various anthropometric and osteodensitometric measurements and an expected minimal difference in gains of 20%, a rough estimate of the sample size was 80 subjects in either the Ca-suppl. or placebo groups reaching the 52-wk point. This is for a 5% -error (i.e. only 5% chance of finding significance that is not actually present) and a 20% ß-error (i.e. 80% chance of detecting a significant difference if it exists). With an estimate from a similar trial in prepubertal girls that 75% of the subjects will consume the tested foods until the completion of the 1-yr intervention, we decided to enroll at least 100 boys in each group. For both anthropometric and bone variables, gains are expressed in either absolute values (grams per square centimeter per year) or percentage change from baseline as means ± SD. aBMD gains were determined separately for each skeletal site. The average aBMD changes at the five appendicular skeletal sites studied were also calculated. The differences between the Ca-suppl. and placebo groups were evaluated using two-tailed Student’s t test for unpaired values and also expressed as a 95% confidence interval (CI) of the differences. For the differences in gains of osteodensitometric variables, an analysis of covariance was used to control for the influence of gain in both body weight and standing height. A Spearman’s correlation was used for the relationship between FDia aBMD gain and physical activity level. A two-way ANOVA was used to analyze the interaction between calcium supplementation and physical activity on FDia aBMD gain. ANOVA repeated measures analysis was used to report the baseline, yr 1, and 1-yr follow-up aBMD changes in one model. The significance level for two-sided P values was 0.050 for all tests. The data were analyzed using STATA (Stata Corp., College Station, TX) software, version 7.0.

	Results

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Cohort studied and compliance

Among the 235 randomized prepubertal boys with age from 6.5–8.5 yr (mean, 7.44 ± 0.39 yr), 232 had their aBMD measured at baseline and after 1 yr (ITT) (Fig. 1). Changes in all variables are expressed in units per year, although the time interval between the first (preintervention) and second (postintervention) visits was 1.10 ± 0.06 and 1.11 ± 0.06 yr in the placebo and Ca-suppl. groups, respectively. At baseline, there was no difference in the anthropometric characteristics, spontaneous calcium intake, physical activity, or bone densitometry variables among the subjects assigned to consume foods enriched in calcium or not (placebo) (Table 1). From the initial cohort, 174 boys (86 and 88 in the Ca-suppl. and placebo groups, respectively) remained compliant (AT) to the supplements during the whole intervention period (Fig. 1). The other 58 (25%) noncompliant subjects (28 and 30 in the Ca-suppl. and placebo groups, respectively) withdrew from treatment but were remeasured at 1 yr. Among them, median withdrawal time (14.5 wk) from treatment was similar in the Ca-suppl. and placebo groups. In the AT cohort, 97.1 ± 7.2% (n = 86) and 98.9 ± 3.2% (n = 88) of the study foods were consumed throughout the intervention period in the Ca-suppl. and placebo groups, respectively, as estimated by regular interviews of the subjects’ mothers.

Anthropometric and bone mineral mass changes

None of the examined subjects displayed any sign of puberty at the end of intervention. The gains in anthropometric and osteodensitometric variables after 12 months of intervention are shown in Table 2. The progression in both standing height and body weight were quite comparable in both groups (Table 2). At LS, no effect of Ca-suppl. on aBMD gain was observed by ITT or AT, whether expressed in absolute values (Table 2) or in percentage change from baseline (Fig. 2). At FDia, a significantly greater aBMD gain, expressed either in milligrams per square centimeter per year or in percentage change from baseline, was observed in the Ca-suppl. group compared with the placebo group by both ITT (P = 0.006 and P = 0.003, respectively) and AT (P < 0.001 and P < 0.001) analyses. These levels of significance were maintained after adjustment for the gain in both body weight and standing height (Table 2 and Fig. 2). At the other four appendicular sites, namely Rmet, radius diaphysis, and femoral neck and trochanter, the aBMD gain was greater, at least in the AT cohort, in the Ca-suppl. group than in the placebo group. However, the differences were not statistically significant (Table 2 and Fig. 2).

View larger version (33K): [in this window] [in a new window]   FIG. 2. aBMD gains expressed in percentage change from baseline in prepubertal boys consuming food products enriched or not in calcium during 1 yr (AT cohort) or for various lengths of time (ITT cohort). Bars represent means ± SD. The number of subjects in the AT cohort was as follows: placebo (open bars), 88; and calcium-supplemented (dashed bars), 86. In the ITT cohort, numbers were: placebo (open bars), 118; and calcium-supplemented (dashed bars), 114. *, P = 0.003 and 0.002; **, P < 0.001 and P < 0.001 without and after adjustment for the gain in body weight and standing height.

An almost significant relationship was found between aBMD gain at FDia and weight-bearing physical activity (ITT, = 0.12, P = 0.068) but not with total physical activity ( = 0.07, P = 0.27), as expressed in kilocalories per day. The calcium response at the FDia level was slightly greater in boys above [Ca-suppl. (n = 63) vs. placebo (n = 53), 80.0 ± 32.6 vs. 67.2 ± 35.9 mg/cm²·yr; difference, 12.8 (0.2–25.3); P = 0.046] than below [Ca-suppl. (n = 65) vs. placebo (n = 51), 71.4 ± 30.0 vs. 61.9 ± 30.6 mg/cm²·yr; difference, 9.4 (–1.9–20.8); P = 0.10] the median of the weight-bearing physical activity estimate. However, a positive interaction between calcium supplementation and physical activity did not reach statistical significance by two-way ANOVA (P = 0.698).

Influence of calcium exposure

At the femoral sites (neck, trochanter, diaphysis), the difference in aBMD gain between Ca-suppl. and placebo groups was approximatively 10% larger by AT compared with ITT (Table 2 and Fig. 2). Such a greater mean calcium effect by AT compared with ITT was not observed at the level of the two radial sites. The magnitude of the calcium effect was further estimated as the difference in gains (expressed in percentage change from baseline) observed between the Ca-suppl. and placebo groups. At the five appendicular skeletal sites, this calcium effect ranged from 8–35% with a mean value of 25% (Table 2). The difference in the mean increment in appendicular aBMD (five appendicular skeletal sites) was significantly greater among the Ca-suppl. compared with the placebo group [ITT: 5.6 ± 2.8 vs. 4.7 ± 2.6%; difference, 0.9% (95% CI, 0.2–1.6); P = 0.014; and AT: 6.0 ± 2.8 vs. 4.7 ± 2.4%; difference, 1.3% (95% CI, 0.5–2.1); P = 0.002] (Fig. 3).

View larger version (32K): [in this window] [in a new window]   FIG. 3. Mean aBMD gains in prepubertal boys consuming food products enriched or not in calcium during 1 yr (AT cohort) or for various lengths of time (ITT cohort). For each subject, the yearly gains recorded at the five appendicular skeletal sites presented in Fig. 2 were averaged. Bars represent means ± SD. The number of subjects in the AT cohort was as follows: placebo (open bars), 84; and calcium-supplemented (dashed bars), 82. In the ITT cohort, numbers were: placebo (open bars), 114; and calcium-supplemented (dashed bars), 109. *, P = 0.014 and P < 0.001; **, P = 0.002 and P < 0.001 without and after adjustment for the gain in body weight and standing height.

None of the differences in bone area and BMC gains between the Ca-suppl. and placebo groups was statistically significant (Table 3). Nevertheless, for FDia and for the mean of the five appendicular sites, there was a much larger gain in BMC than in bone area in favor of the Ca-suppl. group. These differential changes are consistent with the significantly greater aBMD gains in the Ca-suppl. than in the placebo in FDia and in the mean of the five appendicular sites as presented in Table 2 and in Figs. 2 and 3.

The effect of calcium-enriched foods on aBMD gain was further analyzed according to the median of the spontaneous calcium intake as previously performed in prepubertal girls (11). The mean calcium intake was 556 ± 11 (n = 116) and 945 ± 18 mg/d (n = 116) when spontaneous calcium intake was below or above the median, respectively. There was no significant difference between groups: 553 ± 128 (placebo, n = 59) and 560 ± 107 mg/d (Ca-suppl., n = 57) vs. 937 ± 186 (placebo, n = 59) and 954 ± 206 mg/d (Ca-suppl., n = 57), respectively. At baseline, neither statural height nor body weight differed significantly between these groups (height, 125.9 ± 5.9 and 124.4 ± 5.4 cm vs. 126.5 ± 5.7 and 125.7 ± 6.4 cm; weight, 25.3 ± 5.7 and 24.5 ± 3.1 kg vs. 25.6 ± 4.6 and 25.5 ± 4.9 kg). Calcium supplementation did not affect lumbar spine aBMD gain in any of the subgroups (data not shown). In the five appendicular skeletal sites, the difference in mean aBMD gain in response to calcium supplementation was not greater in boys with spontaneous calcium intake below the median compared with those above the median (data not shown). In both subgroups, there was no statistically significant difference in baseline aBMD at any skeletal site between the Ca-suppl.- and placebo-assigned subjects (data not shown).

Follow-up 1 yr after end of intervention

A total of 172 boys (Ca-suppl., n = 85; placebo, n = 87) compliant with the trial foods during the first year were reexamined 1 yr after the end of the intervention (Fig. 1). Spontaneous calcium intakes evaluated at the end of the follow-up period were similar to baseline, 787 ± 354 and 749 ± 315 mg/d in the Ca-suppl. and placebo groups, respectively. The maintenance of a greater gain in appendicular aBMD, before and after adjustment for the gain in body weight and standing height, was found in the cohort of boys having all consumed the calcium-enriched foods until the end of the intervention year. Thus, 1 yr after the end of intervention, the following gains in aBMD were recorded: RMet, 25.3 ± 21.4 vs. 16.5 ± 16.5 mg/cm²·yr; difference, 8.8 (95% CI, 3.0–14.6), P = 0.003 and P < 0.001; FDia, 135.1 ± 42.3 vs. 123.7 ± 37.6 mg/cm²·yr; difference, 11.4 (95% CI, –0.7–23.4); P = 0.064 and P < 0.001; and mean of the five appendicular skeletal sites, 57.6 ± 18.4 vs. 51.4 ± 18.1 mg/cm²·yr; difference, 6.1 (95% CI, 0.6–11.7), P = 0.030 and P < 0.001, in the Ca-suppl. and placebo groups, respectively (Table 4). These aBMD gains, expressed in percentage change from baseline at the end of a 12-month calcium intervention and 1 yr after the end of intervention, were statistically significant as reported in one model by ANOVA repeated measures analysis at RMet (P = 0.010), FDia (P = 0.004), and at the mean of the five appendicular skeletal sites (P = 0.002) (Fig. 4). The corresponding P values in the ITT cohort were P = 0.054, 0.080, and 0.073, respectively.

View larger version (26K): [in this window] [in a new window]   FIG. 4. Gain in aBMD, as expressed in percentage change from baseline, in the five appendicular sites of prepubertal boys (AT cohort). The data correspond to the end of intervention (12 months) and 1 yr (24 months) after discontinuation of the calcium supplementation (continuous line) or placebo (dotted line). The number of subjects was as follows: placebo, 87; and calcium-supplemented, 85. #, P = 0.010; *, P = 0.004; +, P = 0.002 by ANOVA repeated measures analysis.

	Discussion

Top Abstract Introduction Subjects and Methods Results Discussion References

Site selectivity

A positive difference in favor of the calcium-supplemented boys was only observed at appendicular skeletal sites but not at the lumbar spine. The unresponsiveness of the axial site to calcium supplementation was recorded with both ITT and AT. This differential response corroborates previous data obtained in a small cohort of 22 prepubertal twin pairs (3), as well as results recorded in a larger group of 7- to 9-yr-old prepubertal girls enrolled in a trial quite similar to that described in the present report (11). As indicated in a review on the role of calcium on bone health during childhood, most intervention studies that included an axial skeletal site measurement did not find a greater yearly increase in lumbar bone mineral mass accrual in the calcium-supplemented compared with the placebo group (17). This could be due to a greater impact of calcium supplementation on vertebral bone area than on BMC gains at that site. The asynchrony between the greater progression in bone size compared with mineral accumulation is maximal at peak height velocity (18, 19, 20). Thus, in boys, this dissociation is observed around 14 yr of age, i.e. at least 4–5 yr later than the mean age (8.5 yr) of our cohort at the end of the calcium intervention phase. Furthermore, as presented in Table 3, at LS, the increase in bone area compared with BMC gain was not greater in the Ca.-suppl. than in the placebo group. Therefore, it is unlikely that the absence of calcium effect on LS aBMD gain could be ascribed to such a differential tempo in vertebral growth and mineral accumulation within the vertebral body. Thus, the appendicular skeleton appears to be more sensitive than the axial skeleton to the effect of calcium supplementation. Among appendicular regions, the clearest effect was observed in the FDia, a weight-bearing site essentially consisting of compact bone. Nevertheless, aBMD gain could also be positively influenced by calcium supplementation in regions including both cortical and trabecular bone tissues, such as trochanter and radial metaphysis.

At the three femoral sites, the difference in aBMD gain between Ca-suppl. and placebo groups was approximatively 10% higher in the AT compared with the ITT cohort. Such a trend for a dose-response effect was not observed at the level of the two radial sites. It suggests that the response of the forearm might be threshold-dependent rather than dose-dependent.

Spontaneous calcium intake and response to supplementation

Analysis of the results according to the spontaneous calcium intake did not reveal a greater response among boys who had relatively low calcium intake. This observation differs from our previous study in prepubertal girls who underwent the same type of intervention (11). In this previous trial, the positive effect of calcium was significantly larger in girls with a spontaneous calcium intake below (mean = 675 mg/d) than above (mean = 1185 mg/d) the median, which was estimated at 880 mg/d in the AT cohort (11). This analysis suggested that in 7- to 9-yr-old prepubertal girls, 1200 mg/d was very close to the maximum calcium intake for optimal bone mineral mass accrual. The current study in prepubertal boys was not designed to investigate the influence of the spontaneous calcium intake on the effect of supplementation. Indeed, on purpose, we did not enroll boys with a calcium intake above the 75th percentile at baseline. This selection could explain why the difference in the mean response between the Ca-suppl. and the placebo group was not greater in those boys with a spontaneous calcium intake below (mean = 561 mg/d) than above (mean = 968 mg/d) the median, which was estimated at 730 mg/d in the AT cohort. Taking into account this difference in the spontaneous calcium intake between the former study (11) and the present study, it is not possible to establish that the nearly maximal intake for optimal bone mass mineral accrual be set at a higher level, i.e. above 1200 mg/d, in 7- to 9-yr-old prepubertal boys compared with girls in the same age range.

Physical activity and response to calcium supplementation

The difference observed according to the degree of exposure to calcium supplementation between femoral and radial sites might be related to some differential interaction with physical activity at the level of weight-bearing compared with non-weight-bearing skeletal structures (21, 22). The calcium response at the FDia aBMD level was slightly greater in boys above ( gain Ca-suppl. minus placebo, +13 mg/cm²·yr, P = 0.046) than below ( gain Ca-suppl. minus placebo, +9 mg/cm²·yr, P = 0.11), the median of the weight-bearing physical activity estimate. However, a positive interaction between calcium supplementation and physical activity did not reach statistical significance. It is possible that the statistically significant evidence of such a synergism between two environmental factors that exert a positive impact on bone accrual during growth would still require a larger sample size than that of this study.

Bone size and standing height

In this study, the positive effect of milk-extracted calcium salt on aBMD in the appendicular skeleton was not associated with significant increase in bone size or standing height. Therefore, the presence of an association (11, 12, 23) or not (3, 4, 6, 9), as in the present study, of an effect on bone size and standing height cannot be merely ascribed to the nature of the supplemented calcium salt, as previously suggested (11). In girls, the observed calcium effect on bone size and standing height appeared to be transient and possibly related to an acceleration of pubertal maturation (13, 14).

Follow-up after discontinuation of calcium supplementation

The extent to which any benefit on bone mineral mass accrual may be maintained after discontinuation of the intervention remains uncertain. Thus, three follow-up studies have suggested that the effects of calcium on aBMD gain would not be maintained beyond the period of supplementation (5, 24, 25). In contrast, we observed that the benefit was maintained 1 yr (11), 3.5 yr, (13) and even 7.5 yr (14) after the end of intervention in prepubertal girls. As for the effect on bone size, we initially suggested that the contrasting results might be related to the chemical nature of the Ca-suppl.: citrate malate or carbonate salt in the negative studies (5, 24, 25), and phosphate salt as extracted from milk in the positive follow-up study (11). The present study using calcium phosphate salt extracted from milk would favor this hypothesis because the benefit was not lost 1 yr after discontinuation of calcium supplementation, at least in the cohort of boys who kept consuming the tested foods until the end of intervention. However, a recent study does not support this hypothesis because the benefit of bone mineral mass accrual obtained with calcium carbonate supplementation was maintained 1 yr after the end of intervention (26). Therefore, the reason why the benefit of calcium supplementation during childhood may or may not be maintained remains unknown. This issue needs to be further addressed not only because it may shed light on the mechanism by which calcium can affect aBMD increase but also because it is of importance for public health dietary recommendations in the context of early prevention of adult osteoporosis.

In conclusion, this prospective randomized controlled study in prepubertal boys showed that increasing the calcium intake induced a greater aBMD gain in the appendicular but not in the axial skeleton. The calcium effect on aBMD was not associated with a greater gain in bone size or standing height. Finally, this study in prepubertal boys indicates that the benefit on aBMD is not lost 1 yr after the end of intervention. Whether this benefit will be maintained until attainment of peak bone mass remains to be established before considering that increasing calcium consumption in boys during childhood is an efficient measure in the primary prevention of osteoporosis in men.

	Acknowledgments

 
We thank Muriel Füeg-Clarisse and Véronique Pidoux, certified dieticians, for the assessment of food intakes and having carried out this study; François Herrmann, M.D., M.P.H., for help with statistical analysis; Helena Francisco for administrative help; Marianne Perez for secretarial assistance; and Dr. Denis Barclay, Ph.D. (Nestlé Research Center, Lausanne, Switzerland). We are indebted to the Geneva Public Youth Service for the recruitment of the subjects; the team of the bone densitometry unit; and Prof. S. Suter, M.D., chairperson of the Department of Pediatrics, for her constant and invaluable support in this research project.

	Footnotes

 
This work was supported by the Swiss National Science Foundation (Grants 32-49757-96 and 32-58962.99), by Nestec Ltd. (Lausanne, Switzerland), and by Institute Candia (Ivry sur Seine, France).

First Published Online March 8, 2005

Abbreviations: aBMD, Areal bone mineral density; AT, active treatment analysis; BMC, bone mineral content; BMI, body mass index; Ca-suppl., calcium supplement; CI, confidence interval; FDia, femoral diaphysis; ITT, intention-to-treat analysis; LS, lumbar spine; RMet, distal metaphysis.

Received July 23, 2004.

Accepted February 28, 2005.

	References

Top Abstract Introduction Subjects and Methods Results Discussion References

 

1. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B 2000 Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674[CrossRef][Medline]
2. Matkovic V, Fontana D, Tominac C, Goel P, Chesnut 3rd CH 1990 Factors that influence peak bone mass formation: a study of calcium balance and the inheritance of bone mass in adolescent females. Am J Clin Nutr 52:878–888[Abstract/Free Full Text]
3. Johnston Jr CC, Miller JZ, Slemenda CW, Reister TK, Hui S, Christian JC, Peacock M 1992 Calcium supplementation and increases in bone mineral density in children. N Engl J Med 327:82–87[Abstract]
4. Lloyd T, Andon MB, Rollings N, Martel JK, Landis JR, Demers LM, Eggli DF, Kieselhorst K, Kulin HE 1993 Calcium supplementation and bone mineral density in adolescent girls. JAMA 270:841–844[Abstract/Free Full Text]
5. Lloyd T, Martel JK, Rollings N, Andon MB, Kulin H, Demers LM, Eggli DF, Kieselhorst K, Chinchilli VM 1996 The effect of calcium supplementation and Tanner stage on bone density, content and area in teenage women. Osteoporos Int 6:276–283[Medline]
6. Lee WT, Leung SS, Wang SH, Xu YC, Zeng WP, Lau J, Oppenheimer SJ, Cheng JC 1994 Double-blind, controlled calcium supplementation and bone mineral accretion in children accustomed to a low-calcium diet. Am J Clin Nutr 60:744–750[Abstract/Free Full Text]
7. Lee WT, Leung SS, Leung DM, Tsang HS, Lau J, Cheng JC 1995 A randomized double-blind controlled calcium supplementation trial, and bone and height acquisition in children. Br J Nutr 74:125–139[CrossRef][Medline]
8. Chan GM, Hoffman K, McMurry M 1995 Effects of dairy products on bone and body composition in pubertal girls. J Pediatr 126:551–556[CrossRef][Medline]
9. Nowson CA, Green RM, Hopper JL, Sherwin AJ, Young D, Kaymakci B, Guest CS, Smid M, Larkins RG, Wark JD 1997 A co-twin study of the effect of calcium supplementation on bone density during adolescence. Osteoporos Int 7:219–225[CrossRef][Medline]
10. Dibba B, Prentice A, Ceesay M, Stirling DM, Cole TJ, Poskitt EM 2000 Effect of calcium supplementation on bone mineral accretion in Gambian children accustomed to a low-calcium diet. Am J Clin Nutr 71:544–549[Abstract/Free Full Text]
11. Bonjour JP, Carrie AL, Ferrari S, Clavien H, Slosman D, Theintz G, Rizzoli R 1997 Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest 99:1287–1294[Medline]
12. Cadogan J, Eastell R, Jones N, Barker ME 1997 Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial. BMJ 315:1255–1260[Abstract/Free Full Text]
13. Bonjour JP, Chevalley T, Ammann P, Slosman D, Rizzoli R 2001 Gain in bone mineral mass in prepubertal girls 3.5 years after discontinuation of calcium supplementation: a follow-up study. Lancet 358:1208–1212[CrossRef][Medline]
14. Chevalley T, Bonjour JP, Ferrari S, Hans D, Slosman D, Rizzoli R 2005 Interdependence between calcium intake and menarcheal age on bone mass gain: an 8 years follow-up study from pre-puberty to post-menarche. J Clin Endocrinol Metab 90:44–51[Abstract/Free Full Text]
15. Boot AM, de Ridder MA, Pols HA, Krenning EP, de Muinck Keizer-Schrama SM 1997 Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin Endocrinol Metab 82:57–62[Abstract/Free Full Text]
16. Ainsworth BE, Haskell WL, Leon AS, Jacobs Jr DR, Montoye HJ, Sallis JF, Paffenbarger Jr RS 1993 Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc 25:71–80[Medline]
17. Wosje KS, Specker BL 2000 Role of calcium in bone health during childhood. Nutr Rev 58:253–268[Medline]
18. Bailey DA, Wedge JH, McCulloch RG, Martin AD, Bernhardson SC 1989 Epidemiology of fractures of the distal end of the radius in children as associated with growth. J Bone Joint Surg Am 71:1225–1231[Abstract/Free Full Text]
19. Bailey DA, Martin AD, McKay HA, Whiting S, Mirwald R 2000 Calcium accretion in girls and boys during puberty: a longitudinal analysis. J Bone Miner Res 15:2245–2250[CrossRef][Medline]
20. Fournier PE, Rizzoli R, Slosman DO, Theintz G, Bonjour JP 1997 Asynchrony between the rates of standing height gain and bone mass accumulation during puberty. Osteoporos Int 7:525–532[Medline]
21. MacKelvie KJ, Petit MA, Khan KM, Beck TJ, McKay HA 2004 Bone mass and structure are enhanced following a 2-year randomized controlled trial of exercise in prepubertal boys. Bone 34:755–764[Medline]
22. Rowlands AV, Ingledew DK, Powell SM, Eston RG 2004 Interactive effects of habitual physical activity and calcium intake on bone density in boys and girls. J Appl Physiol 97:1203–1208[Abstract/Free Full Text]
23. Prentice A 2002 Calcium supplementation increases height and bone mass in 16–18 year old boys. J Bone Miner Res 17:S397
24. Lee WT, Leung SS, Leung DM, Cheng JC 1996 A follow-up study on the effects of calcium-supplement withdrawal and puberty on bone acquisition of children. Am J Clin Nutr 64:71–77[Abstract/Free Full Text]
25. Slemenda CW, Peacock M, Hui S, Zhou L, Johnston CC 1997 Reduced rates of skeletal remodeling are associated with increased bone mineral density during the development of peak skeletal mass. J Bone Miner Res 12:676–682[CrossRef][Medline]
26. Dibba B, Prentice A, Ceesay M, Mendy M, Darboe S, Stirling DM, Cole TJ, Poskitt EM 2002 Bone mineral contents and plasma osteocalcin concentrations of Gambian children 12 and 24 mo after the withdrawal of a calcium supplement. Am J Clin Nutr 76:681–686[Abstract/Free Full Text]

This article has been cited by other articles:

				L. Richert, T. Chevalley, D. Manen, J.-P. Bonjour, R. Rizzoli, and S. Ferrari Bone Mass in Prepubertal Boys Is Associated with a Gln223Arg Amino Acid Substitution in the Leptin Receptor J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4380 - 4386. [Abstract] [Full Text] [PDF]

				M. Gugatschka, H. Dobnig, A. Fahrleitner-Pammer, P. Pietschmann, S. Kudlacek, A. Strele, and B. Obermayer-Pietsch Molecularly-defined lactose malabsorption, milk consumption and anthropometric differences in adult males QJM, December 1, 2005; 98(12): 857 - 863. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chevalley, T. Articles by Rizzoli, R. Search for Related Content PubMed PubMed Citation Articles by Chevalley, T. Articles by Rizzoli, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL Medline Plus Health Information Dietary Supplements Related Collections Adrenal and Hypertension